The predictive value of bleeding score on the diagnosis of Von Willebrand disease in children applied to the hematologic clinic with epistaxis

Aim: Epistaxis may be a symptom of an inherited bleeding disease.. We aimed to analyze an approved pediatric bleeding score (PBS) as a screening test for von Willebrand Disease (VWD) in children with epistaxis Material and Method: We retrospectively reviewed the medical records of pediatric patients, who applied to the Pediatric Hematology Department with the complaint of epistaxis between January 2018 and December 2019. Results: One hundred and sixty eight patients enrolled in this study There were 65(38.7%) girls and 103(61.3%) boys, with a mean age of 114±49 months (range 8 months to 18 years).The PBS of 34 patients was greater than/ or equal to 2. Factor 8, von Willebrand factor antigen, and von Willebrand Ristocetin cofactor levels were significantly lower in patients with PBS≥2 compared to those in patients with PBS

___

  • Sandoval C, Dong S, Visintainer P, Ozkaynak MF, Jayabose S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol 2002; 47-9.
  • Recht M, Chitlur M, Lam D. Epistaxis as a common presenting symptom of Glanzmann’s thrombasthenia, a rare qualitative platelet disorder: illustrative case examples. Case Rep Emerg Med 2017; 2017: 8796425.
  • Natalia Rydz , Paula D James. The evolution and value of bleeding assessment tools. J Thromb Haemost 2012; 10: 2223-9.
  • Sarah H O'Brien. Bleeding scores: are they really useful? Hematology Am Soc Hematol Educ Program 2012; 2012: 152-6.
  • Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7: 1418–21.
  • Bui J, Martyres D, James PD, et al. Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years. Pediatr Blood Cancer 2019; 66:e27709
  • Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
  • Rojnuckarin P, Akkawat B, Intragumtornchai T. Von Willebrand factor (VWF) antigen levels and function in healthy Thais. Southeast Asian J Trop Med Public Health 2005; 36: 1292-7.
  • Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: a method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8.
  • Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia 2014; 20: 36-42.
  • Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel Report (USA). Haemophilia 2008; 14: 171-232.
  • Leebeek F, Eikenboom J. Von Willebrand’s disease. N Engl J Med 2016; 375: 2067-80.
  • James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5: 280-300.
  • Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
  • Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 2008; 14: 415-22.
  • Biss TT, Blanchette VS, Bowman M, et al. Quantification of bleeding symptoms in children with von Willebrand disease or a platelet function disorder: use of a standardized pediatric bleeding score. Blood 2007; 110: 636a.
  • Belen B, Kocak U, Isik M, et al. Evaluation of pediatric bleeding questionnaire in Turkish children with Von Willebrand disease and platelet function disorders. Clin Appl Thromb Hemost 2015; 21: 565-9.
  • Malec LM, Moore CG. Validation study of the composite score to identify Von Willebrand disease in children. J Pediatr Hematol Oncol 2016; 38: 139-42.